Weekly Issue — 2025-10-12

A conventional stress ECG asks one question: does your heart's electrical activity stay clean as workload rises? CPET asks a broader one. While you pedal or run, a mask captures every breath, and a metabolic cart tracks how much oxygen you consume, how much carbon dioxide you produce, and how efficiently your body shifts from fat- to carbohydrate-dominant fuel as intensity climbs. The 2025 review describes CPET as a tool that provides comprehensive physiological insights into the integrated function of cardiovascular, respiratory, and metabolic systems, exploiting the interactions between those systems rather than isolating one.

In practice that means a single 30- to 60-minute session yields a panel of numbers — peak oxygen uptake (VO2max), ventilatory thresholds, breathing efficiency, heart-rate response — that together describe how your engine actually works under load. A stress ECG, by comparison, mostly tells you whether the wiring sparks.

CPET is not new. What is new — and what drives the review's argument — is the interpretation layer. CPET data is rich, but reading it well has historically required scarce expertise, and two qualified readers can disagree on the same trace. The review notes that AI has introduced a transformative approach to CPET interpretation, enhancing accuracy, efficiency, and clinical decision-making, with potential benefits including improved diagnostic accuracy, reduced interobserver variability and faster decisions.

That last point is the quiet revolution. If algorithms can flatten the expertise gap, a test that once lived in academic cardiopulmonary labs becomes deployable in the kind of preventive clinic an executive might actually visit between meetings. The review frames this as the mechanism by which CPET could plausibly displace the stress ECG as the preferred screening tool in preventive medicine.

The case here rests on a single high-quality review, not a head-to-head outcomes trial showing that CPET-led screening prevents more heart attacks than stress-ECG-led screening. That distinction matters. The review's own authors flag open issues around data quality, model interpretability, and ethical concerns in deploying AI for CPET interpretation — the standard caveats for any AI-in-medicine story, and reasons to read marketing copy from clinics with a careful eye.

Translation for the calendar-driven reader: the direction of travel is credible, the destination is not yet settled standard of care. If your physician still orders a stress ECG, that is not negligence. If a longevity clinic offers CPET as a premium upgrade, that is not snake oil. Both can be defensible; the right answer depends on what question you are trying to answer about your own physiology.

For readers who already treat sleep, training load and bloodwork as quarterly KPIs, CPET is a logical next instrument: it produces metrics — VO2max chief among them — that connect cleanly to the way endurance athletes and longevity-minded physicians already talk about capacity and risk. The 2025 review's contribution is to make the case that, with AI in the loop, this richer test is finally practical at preventive-medicine scale rather than reserved for elite sports science or advanced cardiology referrals.

Treat the shift as moderate-strength evidence pointing in a sensible direction. The treadmill stress ECG is not obsolete tomorrow morning. But if the next time you book a deep cardiac evaluation, your clinician offers CPET with a clearly explained interpretation workflow, the science now supports taking that option seriously — and asking better questions about what the numbers mean for the next decade of your calendar.

The headline number is genuine. According to a 2025 review in the Journal of Peptide Science, more than 11% of all new pharmaceutical chemical entities authorized by the FDA between 2016 and 2024 were synthetically manufactured peptides — a remarkable share for a class that, a decade ago, sat at the margins of drug development. The same review frames the reason for the surge in familiar terms: high selectivity, generally favorable side-effect profiles, and a chemistry that increasingly lends itself to scaled manufacturing. That is the optimistic half of the story, and it is the half that has filtered into wellness culture.

The other half is harder to fit on an Instagram carousel. The review's central argument is that immunogenicity — an unintended or adverse immune response to a peptide therapy — is a critical factor that can limit both the safety and efficacy of these drugs. The mechanism is not exotic. Your immune system is in the business of pattern recognition. Introduce a molecule it reads as foreign, or a familiar molecule presented in an unfamiliar context, and it may respond by generating antidrug antibodies (ADAs). Those antibodies can neutralize the drug, alter its pharmacokinetics, or in some cases provoke a broader inflammatory response.

The review is precise about where the risk originates, and the distinction matters for anyone reading a compounding-pharmacy COA. An adverse immune response, the authors note, may be triggered by the peptide itself or by impurities introduced during production or formulation. Two doors, in other words. The first is intrinsic to the molecule's sequence and structure. The second is a function of how, and how cleanly, it was made.

For approved therapeutics moving through a market-authorization process, both doors are inspected. Current regulatory guidelines require assessment of these risks, including identifying drug impurity levels and conducting immunogenicity testing. The reason that requirement exists is that ADAs are not always predictable from the peptide's primary sequence alone — manufacturing residues, aggregation, and excipient choices can all shift the immune read-out. Designing assays that capture this complexity, and that account for variation in immune response across the human population, is the work the review calls for more of.

That regulatory framing is the part of the story most relevant to readers whose peptides arrive from sources outside that framework. A compound sold for "research use only," a lyophilized vial from a wellness clinic operating under a compounding exemption, or a product purchased through channels that bypass pharmacy oversight entirely — none of these are obligated to perform the immunogenicity workup that an approved biologic must pass before reaching a patient.

One of the more interesting forward-looking observations in the review is that the chemistry itself is changing. As the industry shifts toward greener synthesis methods — reducing solvent waste, swapping reagents, redesigning coupling steps — the impurity fingerprint of a finished peptide changes too. The review's authors flag this directly: the move toward greener chemistries in peptide synthesis may require reassessment of novel impurities in peptide formulations, which is to say that yesterday's safety dataset does not automatically vouch for today's molecule.

For the n-of-1 community, this has a practical implication that gets lost in protocol discussions. Two vials labeled with the same peptide name, produced by two facilities using different synthesis routes, are not interchangeable from an immunogenicity standpoint. The active molecule may be nominally identical; the trace impurity profile almost certainly is not. And it is precisely those impurities — not the headline sequence — that regulators are increasingly being asked to characterize.

The biohacker instinct is to optimize what can be measured. The uncomfortable feature of immunogenicity is that the home toolkit doesn't reach it. A continuous glucose monitor will not flag the development of antidrug antibodies. A ring will not detect a slow shift in a peptide's pharmacokinetics after weeks of subclinical immune recognition. The relevant assays exist — they are the same ones regulators ask sponsors to develop — but they live in pharmaceutical labs, not consumer apps.

The honest read of the current evidence, as the 2025 review frames it, is that immunogenicity is a known and actively studied risk for the approved peptide class, and that the assessment of impurities and immune response is a regulatory expectation rather than an optional add-on. None of this is a verdict on any specific peptide. It is, however, an argument for taking seriously the gap between products that have moved through that assessment and products that have not — and for raising the question with a clinician who can interpret it in the context of an individual's health.

The peptide story is, on balance, a story about a maturing class of medicines. The same review that flags immunogenicity also makes clear why these molecules have earned their seat at the table. The frontier question is not whether peptides work. It is whether the version reaching a given person has been examined for the quieter ways it might not.

The review, by Seth and colleagues, is a synthesis rather than a new trial. Its authors comb through large cohort studies and clinical trials to ask a deceptively simple question: in an era of effective drugs, how much of the cardiometabolic burden can still be moved by the things humans do every day? Their answer is measured. Lifestyle and pharmacotherapy, they argue, have emerged together as the new pillars of preventive medicine — not as rivals, but as a combined strategy whose parts each pull weight.

That framing matters because the public conversation has drifted toward an implicit either/or. If a weekly injection can produce double-digit weight loss, why bother with the harder, slower work of changing what is on the plate or how the afternoon is spent? The review’s response is not a moral one. It is mechanistic. Diabetes, obesity and cardiovascular disease share a common biology of systemic inflammation, insulin resistance and neurohormonal activation, and those pathways respond to inputs that no drug fully replicates: the composition of the diet, the load placed on skeletal muscle, the presence or absence of cigarette smoke.

Three interventions recur across the evidence the authors review. A Mediterranean or plant-forward eating pattern. Structured physical activity and exercise training. Smoking cessation, with a reduction in alcohol intake as a useful adjunct. None of these are novel. All of them, according to the review, have shown promise in mitigating the risks that drive cardiometabolic disease.

The word promise is doing real work in that sentence. This is a review, not a randomized trial, and the underlying evidence base is heterogeneous — cohort studies sit alongside intervention trials of varying size and duration. The editorial evidence rating for this piece is moderate for a reason: the direction of effect is consistent and biologically plausible, but the precise magnitude any individual reader can expect remains uncertain. What the literature supports is a confident statement about pattern, not a precise promise about outcome.

It also helps to be specific about what these interventions are not. A Mediterranean pattern is not a branded program; it is a default — plants, legumes, olive oil, fish, modest dairy, with refined carbohydrates and processed meats stepping back. Structured exercise is not a punishing gym habit; the review treats it as a category that includes both aerobic conditioning and resistance training, prescribed with the same seriousness as a medication. Smoking cessation is the single most leveraged change a current smoker can make for their cardiovascular future, and the review reiterates it without hedging.

The review does not dismiss pharmacotherapy. Its central argument is integrative: lifestyle and medication are now positioned together as new pillars of preventive medicine, and the authors are explicit that only a multifaceted, sustained approach will move long-term outcomes. For readers on or considering GLP-1s, that is the operative phrase. The drugs reduce appetite and body weight in ways that are genuinely new. They do not, on their own, build the muscle that protects glucose handling in later life, restructure a dinner plate, or eliminate the cardiovascular risk that comes with continued smoking.

This is also where the lifestyle conversation becomes especially relevant for people taking these medications. GLP-1 therapy reduces overall food intake, which makes the quality of remaining intake — protein adequacy, fiber, micronutrients — more rather than less important. The Herz review does not address GLP-1 co-management directly, but its insistence on integration is a reasonable lens through which to read the question. This is a conversation to have with a prescribing clinician, not a magazine, but it is the right conversation to have.

The most useful posture for a reader of this literature is neither lifestyle purism nor pharmacological maximalism. It is the recognition that the underlying disease processes — inflammation, insulin resistance, neurohormonal activation — are influenced by multiple inputs at once, and that an intervention that addresses one mechanism does not exempt the others.

That is a less satisfying story than a single miracle, and it is also closer to how prevention actually works. The Herz review is, in the end, a corrective rather than a revelation. It reminds clinicians and patients that the boring instruments — what is eaten, how the body is moved, whether cigarettes are still in the picture — were never demoted by the arrival of new drugs. They were joined.